Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative chemotherapy plus tislelizumab for locally advanced Siewert II/III gastro-esophageal junction adenocarcinoma
ChiCTR2200061906Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: major pathological response and event-free survival. Started Jul 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200061906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061906.